Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention

• Main Authors: Bin YANG, Chunyan ZHENG, Haichu YU, Rui ZHANG, Shan LI, Lijuan TAN, Min LENG, Shanglang CAI
• Format: Article
• Language: English
• Published: Tehran University of Medical Sciences 2018-07-01
• Series: Iranian Journal of Public Health
• Subjects: Ticagrelor; Clopidogrel resistance; Acute myocardial infarction; Thrombelastogram; Major adverse cardiac events
• Online Access: https://ijph.tums.ac.ir/index.php/ijph/article/view/14036

Background: We compared treatments with the antiplatelets ticagrelor and clopidogrel used in patients with acute myocardial infarction (AMI) during the perioperative period for emergency percutaneous coronary intervention (PCI). Methods: A total of 120 patients were selected and randomly divided into control and observation groups (60 patients in each) from 2014- 2016 at The Affiliated Hospital of Qingdao University. The patients in the control group received 300 mg clopidogrel and 300 mg aspirin for oral administration, while those in the observation group were given 180 mg ticagrelor and 300 mg aspirin orally prior to the PCI. During the operation, heparinization and a tirofiban micro-pump were used continuously. Results: Coronary artery and peripheral venous blood were extracted from each patient to obtain various parameters of thrombelastogram (TEG), and the maximum platelet aggregation rates in order to compare antiplatelet effects. Major adverse cardiac events (MACE) were recorded during the following 6-month follow-up. Analysis of the data showed no differences in terms of the time span between medication intake and stent implantation, or the dosage of heparin and tirofiban used between the two groups. Before stent implantation, and 24 and 48 h after the procedure the average R and K values of TEG in coronary artery blood and peripheral venous blood samples in the observation group were longer than those in the control group, while the α angle, MA, CI, MARAA and MARADP values were lower (P<0.05). Conclusion: Ticagrelor can improve antiplatelet treatment for patients with AMI during the perioperative period of emergency PCI.